Dan Ashley , acclaimed journalist and ABC-7 San Francisco Bay Area News anchor, will serve as the emcee for World AIDS Day. Honored with a park bench in the National AIDS Memorial Grove for his ...

GILD has put up a solid performance in the past six months on positive data readouts and strong quarterly results. We believe there is more room for growth, given GILD's strong fundamentals.

According to a study published in the New England Journal of Medicine, twice-yearly injection of Lenacapavir offers a 96 percent ...

On Wednesday, Gilead Sciences, Inc. (GILD) stock saw a modest uptick, ending the day at $92.41 which represents a slight increase of $1.06 or 1.16% from the prior close of $91.35. The stock opened at ...

Failed to fetch dynamically imported module: https://uk.finance.yahoo.com/assets/_app/immutable/nodes/90.BMDkfsfZ.js ...

While antiviral drugs to treat HIV had been approved a decade earlier, only five out of 33 million people who carried the ...

As breakthroughs in biotechnology accelerate, the sector is primed for significant expansion. With emerging trends like gene ...

The National Medical Products Administration (NMPA) has cleared the drug for triple-negative breast cancer (TNBC), making it ...

Gilead (GILD) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.

The Phase III Purpose 2 trial compared the safety and efficacy of twice-yearly subcutaneous lenacapavir for pre-exposure ...

Gilead Sciences demonstrated positive momentum on the NASDAQ, with shares climbing 0.6 percent to $91.88. This upward trajectory is primarily attributed to groundbreaking results from clinical trials ...

In addition, we kept open the possibility that the ETF will continue to rise and could reach around 108.45. To see how we ...